CLINICAL_TRIALS
trial_result
· 2011-06-15
Clinical Trial Update: The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients [Phase 2]
Summary
Phase 2 study evaluating linagliptin (BI 1356) for 24-hour glucose control and biomarkers in adults with Type 2 diabetes, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 2 | Status: COMPLETED | Results posted: 2011-06-15